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Abstract: Introduction: Previously, we demonstrated the degeneration of axon terminals in mice
after repeated injections of blood sera from amyotrophic lateral sclerosis (ALS) patients with identi-
fied mutations. However, whether a similar treatment affects the cell body of motor neurons (MNs)
remained unresolved. Methods: Sera from healthy individuals or ALS patients with a mutation
in different ALS-related genes were intraperitoneally injected into ten-week-old male Balb/c mice
(n = 3/serum) for two days. Afterward, the perikaryal calcium level was measured using electron
microscopy. Furthermore, the optical disector method was used to evaluate the number of lumbar
MNs. Results: The cytoplasmic calcium level of the lumbar MNs of the ALS-serum-treated mice,
compared to untreated and healthy-serum-treated controls, was significantly elevated. While injec-
tions of the healthy serum did not reduce the number of MNs compared to the untreated control
group, ALS sera induced a remarkable loss of MNs. Discussion: Similarly to the distant motor
axon terminals, the injection of blood sera of ALS patients has a rapid degenerative effect on MNs.
Analogously, the magnitude of the evoked changes was specific to the type of mutation; furthermore,
the degeneration was most pronounced in the group treated with sera from ALS patients with a
mutation in the chromosome 9 open reading frame 72 gene.
Keywords: amyotrophic lateral sclerosis; passive transfer; blood serum; motoneuronal calcium
increase; motoneuronal loss; C9ORF72
1. Introduction
Amyotrophic lateral sclerosis (ALS) is one of the most common yet still incurable
disorders affecting, primarily, the motor nervous system [1]. Historically, ALS patients
are sorted into two main categories based on previous involvement in the family. Un-
derlying both familiar (5–10% of all ALS patients) and sporadic cases (90–95% of all ALS
patients), not a single pathological process could be identified. Still, several degenerative
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pathways have been recognized, which, through their complex interactions, result in simi-
lar clinical phenotypes [2,3]. The most well-characterized mechanisms include oxidative
stress [4], glutamate excitotoxicity [5], proteinopathies [6], mitochondrial dysfunctions [7],
neuroinflammation [8,9], disturbance in the calcium homeostasis [10], failure in RNA
processing [11] and the axonal transport [12]. Another interesting phenomenon is that
these pathological processes are not limited to ALS, but they can contribute to numerous
neurological disorders such as Alzheimer’s disease, Parkinson’s disease, Huntington’s
disease, and some other neurological diseases as well [13].
The clinical manifestation of ALS starts with fatigue—and as the disease progresses—,
muscle weakness, paralysis, and, eventually, death occurs primarily due to respiratory
failure [14]. One of the most well-known cellular manifestations of the disease besides the
glial scar formation in the lateral tract of the spinal cord is the loss of lower motor neurons
(MNs) in the spinal cord and upper MNs in the brainstem and motor cortex [15,16]. Since
degeneration and the increasing loss of MNs underlies the progressively developing func-
tional deficit of muscular performance characteristic to ALS, animal models are expected
to replicate this feature. Thus, while similarities of the degenerative changes observed
in the motor axon terminals isolated either from the patients’ muscle biopsy samples or
from different animal models can be used as a measure of the appropriateness of the actual
model, based on the pathological findings in the animals’ spinal cord, assumptions can be
set up about the ongoing alterations in the living human spinal cord, which, for ethical rea-
sons, is unavailable for sampling. Indeed, increased synaptic vesicle density and increased
calcium, which were demonstrated in the motor axon terminals in biopsy samples of ALS
patients [17], could also be documented in the neuromuscular synapses of the interosseus
muscle of the superoxide dismutase 1 (SOD1) G93A transgenic mouse, modeling ALS [18].
Similar changes of the motor axon terminals could be observed in a passive transfer model
of the disease, i.e., after injecting the animals with purified immunoglobulin G (IgG) [19]
or whole sera obtained from sporadic ALS patients [20]. In both models, the demonstrated
calcium increase in the spinal MNs implied the importance of the elevated calcium in the
pathomechanism of the disease. Recently, after injecting the whole sera of patients with
identified mutations, similar alteration could be observed in the motor axon terminals
of the interosseus muscle of the injected animals [21], suggesting that calcium-mediated
processes might be the common denominators of the disease, regardless of the presence of
mutations identified in the patients. However, the deleterious effect of the sera from these
patients on the perikarya of the MNs has not been documented yet.
Thus, in the present experiment, the same experimental paradigm was applied as in
our earlier experiments, i.e., sera from the same patients with identified mutations in the
SOD1, C9ORF72, sequestosome 1 (SQSMT1), G2/mitotic-specific cyclin F (CCNF), never in a
mitosis A-related kinase 1 (NEK1), TANK-binding kinase 1 (TBK1) and ubiquilin 2 (UBQLN2)
genes were injected into mice. Afterward, the number of MNs in the ventrolateral motor
pool in the lumbar spinal cord was determined using the optical disector method, and the
calcium content of these cells was analyzed electron microscopically.
2. Results
2.1. Presence of the Human Immunoglobulins in the Spinal Motor Neurons after Passive Transfer
of the Amyotrophic Lateral Sclerosis Sera
Since the whole serum was used for inoculation in this study, the presence of im-
munoglobulins which are partially responsible for the neuronal degeneration was also
visualized using immunohistochemistry [22]. The passive transfer of the ALS sera resulted
in the presence of immunoglobulins in MNs after two consecutive days of treatment; how-
ever, a similar infiltration of immunoglobulins into the MNs was not visible after treatment
with sera from healthy individuals or without any treatment (Figure 1).
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Figure 1. The presence of human immunoglobulins in spinal motor neurons (MNs) can be detected after intraperitoneal 
injection of sera from amyotrophic lateral sclerosis patients (C). The ventrolateral pool of MNs was demonstrated with 
choline acetyltransferase (ChAT) staining (A,D,G). Presence of immunoglobulins can be detected in sections cut from 
ALS-treated mice (B), and were not present in sections obtained from healthy-serum-treated (E) or untreated control ani-
mals (H). Merged images (C,F,I) show the colocalization of human immunoglobulins with MNs of ALS serum-treated 
mice only. Scale bar: 200 µm. 
2.2. Qualitative Morphological Changes of the Lumbar Motor Neurons and Their Calcium Con-
tent after Injection of Amyotrophic Lateral Sclerosis Sera 
The qualitative examination of the ventrolateral MN pool after cresyl violet staining 
did not show any MN loss in the lumbar spinal cord after a passive transfer from healthy 
volunteers compared to the untreated animals (Figure 2). However, the passive transfer 
of ALS sera resulted in a prominent loss of MNs in all groups, but the most notable de-
generation could be observed after inoculation with sera from ALS patients with a muta-
tion in the C9ORF72 gene (Figure 2). 
Figure 1. The presence of human immunoglobulins in spinal motor neurons (MNs) can be detected after intraperitoneal
injection of sera from amyotrophic lateral sclerosis patients (C). The ventrolateral pool of MNs was demonstrated with
choline acetyltransferase (ChAT) staining (A,D,G). Presence of immunoglobulins can be detected in sections cut from
ALS-treated mice (B), and were not present in sections obtained from healthy-serum-treated (E) or untreated control animals
(H). Merged images (C,F,I) show the colocalization of human immunoglobulins with MNs of ALS serum-treated mice only.
Scale bar: 200 µm.
2.2. Qualitative Morphological Changes of the Lumbar Motor Neurons and Their Calcium Content
after Injection of Amyotrophic Lateral Sclerosis Sera
The qualitative exa ination of the ventrolateral N pool after cresyl violet staining
did not sho any loss in the lu bar spinal cord after a passive transfer fro healthy
volunteers co pared to the untreated ani als (Figure 2). o ever, the passive transfer
of ALS sera resulted in a prominent loss of MNs in all groups, but the most notable
degeneration could e observed after inoculation with sera from ALS patients with a
mutation in the C9ORF72 gene (Figure 2).
Electron microscopically, no ultrastructural alteration could be seen in MNs of un-
treated mice or after treatment with serum from healthy controls. After inoculation with
ALS sera, disorganized mitochondrial cristae, furthermore, dilated endoplasmic reticulum
and a Golgi complex could be observed in the perikarya of MNs compared to controls
(Figure 3A,B). Increased cytoplasmic and mitochondrial calcium, visualized as a larger
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number of electron-dense deposits (EDDs), could be observed in MNs after treatment with
sera from ALS patients with identified mutations (Figure 3C,D). Qualitatively, the elevation
in the number of calcium precipitates was most prominent in mice treated with ALS sera
from patients with the C9ORF72 mutation (Figure 3D).




Figure 2. Large cells (>30 µm of characteristic profile size) identified as motor neurons (MNs) are detectable in high num-
ber in untreated mice (A) or after injection with sera from healthy individuals (B). A slight reduction in the number of 
MNs could be observed after treatment with serum from a patient with superoxide dismutase 1 pLeu144Phe mutation (C). 
The most prominent neuronal loss was noted in the group treated with sera from patients with chromosome 9 open reading 
frame 72 hexanucleotide repeat expansions, (D) where almost all MNs diminished. For representative images from other 
groups, see Figure S1. Scale bar: 100 µm. 
Electron microscopically, no ultrastructural alteration could be seen in MNs of un-
treated mice or after treatment with serum from healthy controls. After inoculation with 
ALS sera, disorganized mitochondrial cristae, furthermore, dilated endoplasmic reticu-
lum and a Golgi complex could be observed in the perikarya of MNs compared to controls 
(Figure 3A,B). Increased cytoplasmic and mitochondrial calcium, visualized as a larger 
number of electron-dense deposits (EDDs), could be observed in MNs after treatment with 
sera from ALS patients with identified mutations (Figure 3C,D). Qualitatively, the eleva-
tion in the number of calcium precipitates was most prominent in mice treated with ALS 
sera from patients with the C9ORF72 mutation (Figure 3D). 
Figure 2. Large cells (>30 µm of characteristic profile size) identified as motor neurons (MNs) are detectable in high number
in untreated mice (A) or after injection with sera from healthy individuals (B). A slight reduction in the number of MNs
could be observed after treatment with serum from a patient with superoxide dismutase 1 pLeu144Phe mutation (C). The
most prominent neuronal loss was noted in the group treated with sera from patients with chromosome 9 open reading frame
72 hexanucleotide repeat expansions, (D) where almost all MNs diminished. For representative images from other groups,
see Figure S1. Scale bar: 100 µm.
2.3. Calcium Level Is Elevated in the Perikarya of Lumbar Motor Neurons after Injection of
Amyotrophic Lateral Sclerosis Sera into Mice
The intracellular calcium content was expressed as the volume density of the calcium
precipitates to analyze changes in the calcium levels. For such a quantification, the volume
occupied by EDDs was measured; then, these number was divided with the reference vol-
ume of the cytoplasm. These data showed a significant increase in the calcium level induced
by a passive transfer in all ALS-sera-treated mice (Figure 4). Compared to the untreated and
healthy-serum-treated controls, all animals showed elevated calcium levels. The elevation
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of the intracellular calcium level was most prominent in mice treated with ALS sera from
patients with hexanucleotide repeat expansions (HNRs) in the C9ORF72 gene.




Figure 3. No ultrastructural alterations can be seen in untreated (A) and healthy-serum-treated motor neurons (MNs) (B). 
The dilated lumen of the endoplasmic reticulum and mitochondrial cristae structure characterize the micrographs from 
mice treated with sera from amyotrophic lateral sclerosis (ALS) patients with superoxide dismutase 1 pLeu144Phe mutation 
(C) and chromosome 9 open reading frame 72 hexanucleotide repeat expansions (C9ORF72 HNRs) (D). In the motor neurons 
of ALS-sera-treated mice (C,D), an elevated number of electron-dense deposits (EDDs), representing the calcium content, 
can be seen compared to the MNs of untreated (A) and healthy-sera-treated animals (B). The elevation in the numbers of 
EDDs was most prominent in the group treated with sera from ALS patients with C9ORF72 HNRs (D). For representative 
images from the other groups, see Figure S2. Mit: mitochondrion; rer: rough endoplasmic reticulum; gol: Golgi complex; 
nucl: nucleus. Scale bar: 500 nm. 
2.3. Calcium Level Is Elevated in the Perikarya of Lumbar Motor Neurons after Injection of Am-
yotrophic Lateral Sclerosis Sera into Mice 
The intracellular calcium content was expressed as the volume density of the calcium 
precipitates to analyze changes in the calcium levels. For such a quantification, the volume 
occupied by EDDs was measured; then, these number was divided with the reference vol-
ume of the cytoplasm. These data showed a significant increase in the calcium level in-
duced by a passive transfer in all ALS-sera-treated mice (Figure 4). Compared to the un-
treated and healthy-serum-treated controls, all animals showed elevated calcium levels. 
The elevation of the intracellular calcium level was most prominent in mice treated with 
Figure 3. No ultrastructural alterations can be seen in untreated (A) and healthy-serum-treated motor neurons (MNs)
(B). The dilated lumen of the endoplasmic reticulum and mitochondrial cristae structure characterize the micrographs from
mice treated with sera from amyotrophic lateral sclerosis (ALS) patients with superoxide dismutase 1 pLeu144Phe mutation
(C) and chromosome 9 open reading frame 72 hexanucleotide repeat expansions (C9ORF72 HNRs) (D). In the motor neurons of
ALS-sera-treated mice (C,D), an elevated number of electron-dense deposits (EDDs), representing the calcium content, can
be seen compared to the MNs of untreated (A) and healthy-sera-treated animals (B). The elevation in the numbers of EDDs
was most prominent in the group treated with sera from ALS patients with C9ORF72 HNRs (D). For representat ve i ages
from the other groups, see Figure S2. Mit: mitochondrion; rer: rough endoplasmic reticulum; gol: Golgi complex; nucl:
nucleus. Scale bar: 500 nm.
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Figure 4. A significant elevation in electron-dense deposits can be observed in motor neurons (MNs) of all amyotrophic 
lateral sclerosis sera-treated mice. Animals treated with sera from patients with hexanucleotide repeat expansions in the 
chromosome 9 open reading frame 72 gene showed the highest increase in intracellular calcium levels. Data values are dis-
played within the bars, and represented by mean value ± standard error of the mean. Statistical evaluation was determined 
using one-way analysis of the variance with the Bonferroni post hoc pairwise comparison. *: p < 0.05; **: p < 0.01; ***: p < 
0.001. 
2.4. Number of Lumbar Motor Neurons Is Reduced after Injection of Amyotrophic Lateral Sclero-
sis Sera into Mice 
The number of MNs in the lumbar segment of the spinal cord was determined by the 
optical disector method and expressed as number/mm3. After treatment with sera from 
ALS patients, all injected animals showed neuronal loss, compared to the untreated con-
trols, which was most prominent in mice injected with sera from patients with the 
C9ORF72 mutation (Figure 5). In detail, the number of MNs in the ventrolateral pool of 
the spinal cord was not changed after a passive transfer of the sera from healthy individ-
uals compared to the untreated control. However, all inoculated groups of animals with 
different ALS sera showed a reduced number in this anatomical region. 
Figure 4. A significant elevation in electron-dense deposits can be observed in motor neurons (MNs) of all amyotrophic
lateral sclerosis sera-treated mice. Animals treated with sera from patients with hexanucleotide repeat expansions in the
chromosome 9 open reading frame 72 gene showed the highest increase in intracellular calcium levels. Data values are displayed
within the bars, and repre ented by mean value ± standa d error of the mean. Statistical evaluation was determined using
one-way analysis of the variance with the Bonferroni post hoc pairwise comparison. *: p < 0.05; **: p < 0.01; ***: p < 0.001.
2.4. Number of Lumbar Motor Neurons Is Reduced after Injection of Amyotrophic Lateral Sclerosis
Sera into Mice
The number of MNs in the lumbar segment of the spinal cord was determined by the
optical disector method and expressed as number/mm3. After treatment with sera from
ALS patients, all injected animals showed neuronal loss, compared to the untreated controls,
which was most prominent in mice injected with sera from patients with the C9ORF72
mutation (Figure 5). In detail, the number of MNs in the ventrolateral pool of the spinal
cord was not changed after a passive transfer of the sera from healthy individuals compared
to the untreated control. However, all inoculated groups of animals with different ALS
sera showed a reduced number in this anatomical region.




Figure 5. While there was no difference between the untreated and the healthy-sera-treated animals, the number of motor 
neurons was reduced in all amyotrophic lateral sclerosis sera-treated groups. Data values are displayed within the bars, 
and represented by mean value ± standard error of the mean. Statistical evaluation was determined using one-way anal-
ysis of the variance with the Bonferroni post hoc pairwise comparison. ***: p < 0.001. 
2.5. Correlation of Intracellular Calcium Increase in Motor Neurons and Loss of Spinal Motor 
Neurons of Amyotrophic Lateral Sclerosis Serum-Treated Mice 
Since the central role of calcium in the degeneration process of MNs is well estab-
lished [23], a correlation between the treatment-induced elevation of intracellular calcium 
and the eventual loss of MNs can be implicitly hypothesized. Thus, the cross-relation of 
the intracellular calcium level of MNs and the number of surviving lumbar MNs after a 
passive transfer of ALS sera was analyzed by plotting these parameters after pooling the 
data to individual serum donor patients (Figure 6). The diagram demonstrates that the 
larger the calcium increase induced by the serum from a particular patient, the smaller the 
number of surviving MNs in the spinal cord (Figure 6). The data representing the control 
group were significantly separated from the ALS-serum-treated patients’ data; further-
more, in the ALS-sera-treated group, the data representing the C9ORF72 HNRs formed a 
separate subgroup (Figure 6). 
Figure 5. While there was no difference between the untreated and the healthy-sera-treated animals, the number of motor
neurons was reduced in all amyotrophic lateral sclerosis sera-treated groups. Data values are displayed within the bars, and
represented by mean value ± standard error of the mean. Statistical evaluation was determined using one-way analysis of
the variance with the Bonferroni post hoc pairwise comparison. ***: p < 0.001.
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2.5. Correlation of Intracellular Calcium Increase in Motor Neurons and Loss of Spinal Motor
Neurons of Amyotrophic Lateral Sclerosis Serum-Treated Mice
Since the central role of calcium in the degeneration process of MNs is well estab-
lished [23], a correlation between the treatment-induced elevation of intracellular calcium
and the eventual loss of MNs can be implicitly hypothesized. Thus, the cross-relation of
the intracellular calcium level of MNs and the number of surviving lumbar MNs after a
passive transfer of ALS sera was analyzed by plotting these parameters after pooling the
data to individual serum donor patients (Figure 6). The diagram demonstrates that the
larger the calcium increase induced by the serum from a particular patient, the smaller the
number of surviving MNs in the spinal cord (Figure 6). The data representing the control
group were significantly separated from the ALS-serum-treated patients’ data; furthermore,
in the ALS-sera-treated group, the data representing the C9ORF72 HNRs formed a separate
subgroup (Figure 6).




Figure 6. On the diagram (except for the untreated animals), each symbol represents a patient who served as a serum 
donor. Clearly, by increasing the observed intracellular calcium level (horizontal axis), the decreasing number of surviving 
motor neurons could be counted (vertical axis). With statistical analysis, three clusters could be identified: the control 
group at the left side, the majority of amyotrophic lateral sclerosis patients at the middle, and patients with chromosome 9 
open reading frame 72 hexanucleotide repeats, with the most substantial effect, at the right side. For a visual representation, 
99.5% confidence intervals were determined for the three clusters, drawn as ellipses around the clusters. 
2.6. Correlation of Intracellular Calcium Increase in Motor Neurons and Motor Axon Terminals 
of Amyotrophic Lateral Sclerosis Serum-Treated Mice 
In our previous study, we demonstrated a significant calcium increase in the axon 
terminals of lumbar MNs in a similar experimental paradigm as in the present study [21]. 
To analyze whether analogous changes in the intracellular calcium could be evoked by 
the ALS serum treatment in the peripherally located motor axon terminals and the cen-
trally located motoneuronal cell bodies, calcium data from these anatomical regions were 
pooled to patients serving as serum donors, plotted (Figure 6), and evaluated using a lin-
ear regression analysis. The statistical evaluation showed a strong correlation (R = 0.902) 
between the elevation of the calcium level in the perikarya and axon terminals of lumbar 
MNs represented by the volume density of EDDs (Figure 7). This correlation indicates that 
ALS sera initiated a similar elevation in the calcium level in the MNs and their distant 
axon terminals after a passive transfer compared to untreated and healthy-sera-treated 
controls. 
Figure 6. On t e ( ce t for the untreated animals), each symbol rep sents a patien who served as a serum donor.
Clearly, by increasing the observed intracellular calcium level (horizontal axis), the decreasing number of surviving motor
neurons could be counted (vertical axis). With statistical analysis, three clusters could be identified: the control group
at the left side, the majority of amyotrophic lateral sclerosis patients at the middle, and patients with chromosome 9 open
reading frame 72 hexanucleotide repeats, with the most substantial effect, at the right side. For a visual representation, 99.5%
confidence intervals were determined for the three clusters, drawn as ellipses around the clusters.
2.6. Correlation of Intracellular Calcium Increase in Motor Neurons and Motor Axon Terminals of
Amyotrophic Lateral Sclerosis Serum-Treated Mice
In our previous study, we demonstrated a significant calcium increase in the axon
terminals of lumbar MNs in a similar experimental paradigm as in the present study [21].
To analyze hether analogous changes in the intracellular calcium could be evoked by the
ALS serum treatment in the peripherally located motor axon terminals and the centrally
located motoneuronal cell bodies, calcium data from these anatomical regions were pooled
to patients serving as serum donors, plotted (Figure 6), and evaluated using a linear
regression an lysis. The statistical evaluation sho ed tr rr l ti ( = 0.902)
betw en the elevation of the calcium level in the perikarya and axon terminals of lumbar
MNs represented by the volume density of EDDs (Figure 7). This co relation indicates that
ALS sera i iti si ilar elevation in the calcium lev l in the MNs and their distant axon
terminals after passive transfer compared to untreated and healthy-sera-treated controls.
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Figure 7. Volume densities of the electron-dense deposits from the two anatomical regions of the spinal motor neurons 
(MNs) of injected mice were pooled to patients and plotted in such a way that (except for the untreated animals) each 
symbol represented a patient who served as a serum donor. Passive transfer of amyotrophic lateral sclerosis sera resulted 
in a mutual increase in calcium levels in the central and peripheral parts of the MNs. This observation was corroborated 
by the analysis of the fitted linear model, where the correlation coefficient (R) was 0.902, representing a strong correlation 
between the examined variables. 
3. Discussion 
The implication that circulating toxins might be responsible for the degeneration of 
the anterior horn cells was based on the seminal observation of Wolfgram and Myers de-
scribing that diluted serum, specifically from ALS patients, had a toxic effect on mouse 
anterior horn cells in culture [24]. From the efforts to model sporadic ALS based on circu-
lating agents, those based either on the effect of cerebrospinal fluids [25,26] or of sera from 
the patients [27] can be emphasized. Indeed, a line of research data from Appel’s labora-
tory documented the presence of immunoglobulins in spinal and cortical motor neurons 
[28] and the ability of immunoglobulins from sporadic ALS patients (i) to induce apoptotic 
cell death in a hybrid motoneuron cell line [29], (ii) to increase the Ca2+ current [30] and 
calcium level in motoneurons in vitro [31], and (iii) to increase the intracellular calcium of 
cell bodies and axon terminals of MNs and the increase in synaptic vesicles at the neuro-
muscular synapses, in vivo [19]. The pathobiological relevance of these findings received 
convincing support by delicate structural and microanalytical data displaying comparable 
alterations to human motor axon terminals in muscle biopsy samples obtained from spo-
radic ALS patients [17]. The detrimental effect of ALS-specific antibodies in in vitro and 
in vivo studies is well-known. Still, in the case of a systemic administration, the transport 
mechanisms behind how purified IgG or sera components migrate to the central nervous 
system are poorly understood. One possible explanation might be the disruption of the 
blood–brain barrier and blood–spinal cord barrier, the native barriers between the central 
nervous system and the circulatory system, which are indeed altered in ALS [32,33]. This 
complex anatomical structure has a crucial role in neurodegeneration and potential im-
munotherapies [34,35]. ALS mouse models showed increased permeability of mi-
crovessels for Evans blue at the early stage of the disease [36]. An impairment of the neu-
rovascular unit was demonstrated in the ALS rat model by the decreased expression of 
Figure 7. Volume densities of the electron-dense deposits from the two anatomical regions of the spinal motor neurons
(MNs) of injected mice were pooled to patients and plotted in such a way that (except for the untreated animals) each
symbol represented a patient who served as a serum donor. Passive transfer of amyotrophic lateral sclerosis sera resulted
in a mutual increase in calcium levels in the central and peripheral parts of the MNs. This observation was corroborated
by the analysis of the fitted linear model, where the correlation coefficient (R) was 0.902, representing a strong correlation
between the examined variables.
3. Discussion
The implication that circulating toxins might be responsible for the degeneration of the
anterior horn cells was based on the seminal observation of Wolfgram and Myers describing
that diluted serum, specifically from ALS patients, had a toxic effect on mouse anterior
horn cells in culture [24]. From the efforts to model sporadic ALS based on circulating
agents, those based either on the effect of cerebrospinal fluids [25,26] or of sera from the
patients [27] can be emphasized. Indeed, a line of research data from Appel’s laboratory
documented the presence of immunoglobulins in spinal and cortical motor neurons [28]
and the ability of immunoglobulins from sporadic ALS patients (i) to induce apoptotic
cell death in a hybrid motoneuron cell line [29], (ii) to increase the Ca2+ current [30] and
calcium level in motoneurons in vitro [31], and (iii) to increase the intracellular calcium
of cell bodies and axon terminals of MNs and the increase in synaptic vesicles at the
neuromuscular synapses, in vivo [19]. The pathobiological relevance of these findings
received convincing support by delicate structural and microanalytical data displaying
comparable alterations to human motor axon terminals in muscle biopsy samples obtained
from sporadic ALS patients [17]. The detrimental effect of ALS-specific antibodies in
in vitro and in vivo studies is well-known. Still, in the case of a systemic administration,
the transport mechanisms behind how purified IgG or sera components migrate to the
central nervous system are poorly understood. One possible explanation might be the
disruption of the blood–brain barrier and blood–spinal cord barrier, the native barriers
between the central nervous system and the circulatory syst m, which are indeed altered in
ALS [32,33]. This complex anatomical structure has a crucial role in neurodegeneration and
potential immunotherapies [34,35]. ALS mouse m d ls showed increased permeability of
microve sels for Evans blue at the early stage of th disease [36]. An i pairment of the
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neurovascular unit was demonstrated in the ALS rat model by the decreased expression of
tight junction proteins of endothelial cells as well as zonula occludens and claudin proteins
in the spinal cord [37,38]. Such disruption in the barrier properties promotes the migration
of immunoglobulins [39]; furthermore, the recruitment of immunocompetent cells at the
motor axon terminal also supports the migration of antibodies from the periphery [40].
Such a degeneration of the neuromuscular junction was noted in the mice used in this
study (Figure S3) and our previous study after a long-term inoculation with ALS sera [20].
The availability of sera from patients with no family history of the disease made it
possible to quantitatively characterize the pathological and microchemical abnormalities
and the reduced physical performance induced by the injection of the sera into mice [20].
In two weeks, a repeated injection of ALS serum induced an approximate 60% loss of
MNs at the lumbar section of the spinal cord, accompanied by a 60% loss of physical
performance expressed by the inability to hang on a vertical grid and significant increases
in the intracellular calcium of surviving spinal MNs and in the motor axon terminals,
measured with an electron microscopic histochemical method [20].
Next, to examine whether comparable changes could be induced with sera from
ALS patients with different identified mutations, including those with a documented
family history, were selected as serum donors. Meanwhile, healthy individuals, and
patients with negative screening results for all 35 major ALS genes, regarded as sporadic
ALS patients, served as the control. Using a short-term repeated injection paradigm, an
increased synaptic vesicle density and increased calcium could be detected in the motor
axon terminals of the injected mice [21], similar to those changes detected after the injection
of sera from sporadic ALS patients [20] or seen in muscle biopsy samples of sporadic
patients [17]. Furthermore, on the scatter diagram vesicle number and intracellular calcium,
the population of ALS patients could be separated from the controls [21], again, similarly
as in the case of human samples [17].
To answer whether comparable changes could be induced in the cell bodies of the
spinal MNs as in the axon terminals with the injections of these sera, in the present
experiments, the injections were repeated in the same way as previously using a new set of
animals. Afterward, the cell number and the calcium content of MNs in the lumbar spinal
cord were analyzed. First, a decrease in the number of MNs was observed with increased
intracellular calcium in the surviving population. Interestingly, in the scatter plot of these
parameters, the population of ALS patients could be separated from the controls, similarly
as in the case of the axon terminals [21]. Secondly, the calcium increase in the motor axon
terminals showed a strong correlation with that of the cell bodies, indicating that analogous
changes could be induced in these distant anatomical regions of MNs with the injection
of the same ALS sera. These passive transfer experiments accentuated the similar central
role of calcium in the process of sporadic and familial ALS patients, regardless of the
primary etiological cause of the disease, which might be at least partially responsible for
the clinically similar course of ALS. The general role of calcium in the pathomechanism
of ALS was further supported with the findings obtained in the commonly used SOD1
transgenic model of ALS: a similar motoneuronal loss in the spinal cord with increased
calcium could be observed [18], as documented in the present study.
For the present experiments, instead of purified IgG, sera from ALS patients were used
for the inoculation, as in our previous studies [20,21], because it demonstrates more complex
and more substantial biological effects than the isolated IgG. However, the presence of
immunoglobulins was demonstrated in the spinal MNs. The degenerative effect of ALS
serum might come from multiple pathways. On the one hand, it comes from the presence
of numerous autoimmune IgG antibodies, characterized by the examination of sera from
ALS patients [41]. Besides the autoimmune properties, these antibodies can elevate the
motoneuronal calcium level [42,43] and induce selective MN apoptosis in rat mixed primary
spinal cord cultures [44]. Immunoglobulins from patients with sporadic ALS can bind and
modify the function of L-type, P-type, and other neuronal calcium channels [45–47], which
increase the frequency of miniature end-plate potentials eventually [30]. ALS-specific
Int. J. Mol. Sci. 2021, 22, 9994 10 of 15
immunoglobulins from ALS patients or immunized goats also increased tumor necrosis
factor α, interleukin-6, and interleukin-10 levels in the spinal cord, which are well-known
proinflammatory factors in mice after intraperitoneal administration [48]. The importance
of these autoantibodies in the pathobiology of ALS is further accentuated by the fact that
by neutralizing these antibodies, the pathobiological effects diminish [30]. Admitting that
the subsets of spinal MNs may have different susceptibility [49] to answer whether it
can be attributed to their unique intrinsic properties, e.g., the calcium-binding protein
content [50,51] or different ability to uptake IgG, warrants further studies.
The large extent of motoneuronal loss in the present experiments seemed to be sur-
prising; however, numerous spinal cord injury models showed a fast and significant loss
of MNs. For example, 44% of neurons diminished after one day after dorsal compression,
which peaked at day 3 when almost 75% of the neurons were lost [52]. After spinal tran-
section injury, a rapid neuronal loss was observed 12 h following injury [53]. Similar to
these models, MNs showed a rapid degeneration after a couple of hours in contusion,
compression, and transection models [54,55]. Besides the surgical methods, ischemic injury
can initiate similarly fast neuronal degeneration as well [56]. Furthermore, a fast and
significant loss of MNs could be induced in rat pups with intrathecal injection of ALS
cerebrospinal fluid [26].
In the present study, we demonstrated that, based on the correlation of the cell loss and
the calcium increase, ALS patients could be sorted into clusters different from the controls
as in the case of data obtained in the motor axon terminals [21]. Moreover, a subgroup of
patients with the C9ORF72 mutation could also be identified. The remarkable effect of this
mutation might be attributed to a mixture of the loss of function and a toxic gain of function
of the C9ORF72 protein, along with a strong immune/inflammatory effect [57–59].
In summary, we demonstrated that ALS-like pathological alterations could be induced
in the spinal MNs and axon terminals of the injected animals by injecting the patients’
sera regardless of the known etiological cause of the disease. The induced degeneration of
the MNs accompanied by the calcium increase points to the central role of calcium in the
pathomechanism of the disease, which may be the mediator of a common final pathway of
this degenerative disease [23].
4. Materials and Methods
4.1. Ethical Approvals and Consent to Participate
The protection and welfare of animals were carried out according to the national law
(Edict 40/2013 (II.14)) which conforms to the European Union executory directive on the
protection of animals used for scientific purposes (Directive 2010/63/EU amended by the
Regulation (EU) 2019/1010). Ethical approvals for the scientific experiments involving
animals were given by The Government Office in Csongrád-Csanád County, Hungary
(#XI/4962/2015; #XVI/819/2021) and by The Committee for Animal Experiments of the
University of Szeged, Szeged, Hungary (I. 74-II/2015) and by the Ethical Committee for
the protection of Animals in Scientific Research at the Biological Research Center, Szeged,
Hungary (#XVI/819/2021). All efforts were made to minimize animal suffering throughout
the experiments. Ethical approvals for obtaining and storing blood samples for research
purposes from ALS patients and healthy controls in an anonymous manner were given
by The Human Investigation Review Board, University of Szeged, Hungary (#2557/2009).
All experiments using human samples in our project agreed with the declaration of the
Medical World Federation proclaimed in Helsinki 1964.
4.2. Patients
The same ALS patients and three healthy controls participated in this study as in our
previous work [21]. Among these individuals, five ALS patients possessed mutations in the
SOD1 gene. Three patients had GGGGCC HNRs in the C9ORF72 gene. One patient had a
mutation in the SQSTM1 gene, another one had a mutation in the CCNF gene, a further one
had a mutation in the UBQLN2 gene, and, finally, a patient with ALS and frontotemporal
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dementia had a double mutation in the NEK1 gene together with a mutation in the TBK1
gene, respectively. Two patients, composing the sporadic ALS group, were genetically
screened for all 35 major ALS genes and proved to be negative. For controls, sera from 3
age-matched healthy volunteers were obtained.
4.3. Passive Transfer of the Human Sera and Tissue Preparation for Electron Microscopy
Forty-eight male Balb/c mice, obtained from Charles River Appoints AnimaLab
Hungary Kft. (Vác, Hungary), were injected intraperitoneally with 1 mL/day serum from
ALS patients with different mutations (n = 3) or healthy individuals (n = 3) for two days.
All animals received sera from the same patient during the inoculation period. Afterward,
animals treated with sera with the same mutation were pooled together since there was no
statistical difference between the effect of the sera from different patients with the same
mutation. Therefore, the grouping of the experimental animals was based on the mutations,
not the patients. A similar pooling protocol was applied to animals treated with sera from
sporadic patients. One group of animals did not receive an injection and was used as the
untreated control (n = 3).
During the two-day inoculation period, animals were housed in plastic cages
(5 animals/cage, at most) in a thermoneutral environment (22 ± 3 ◦C) and reversed
12 h light/dark cycle with access to water and regular rodent chow ad libitum. Twenty-four
hours after the last serum injection, lumbar spinal cords were dissected from the animals
for the electron microscopic evaluation of intracellular and suborganellar localization of
calcium in tissue samples as described in our previous study [21].
4.4. Immunohistochemical Demonstration of Human Immunoglobulins in the Lumbar Neurons
To illustrate the presence of human immunoglobulins in spinal neurons, mice after
passive transfer of sera from ALS patients or healthy individuals, or without any treatment,
were anesthetized with Avertin, then transcardially perfused with 10 mM phosphate-
buffered saline (PBS), followed by 4% paraformaldehyde (Σ-Aldrich, St. Louis, MO, USA;
pH adjusted to 7.4 with NaOH). L2–L5 lumbar spinal cord segments were postfixed in the
same fixative for 24 h; then, tissue samples were cryoprotected in 30% sucrose solution.
After all spinal cord tissue was submerged in the solution at 4 ◦C, 30 µm thin sections were
prepared on a freezing microtome (Reichert-Jung, Wetzlar, Germany). Free-floating sections
were rinsed in 10 mM PBS for 5 min (3 times); then, 2% normal goat serum in 10 mM PBS
with 0.2% Triton X-100 (TPBS) was used for 60 min to block non-specific binding sites.
Afterward, samples were incubated with rabbit anti-choline-acetyltransferase antibody
(Thermo Fisher Scientific, Waltham MA, USA) diluted to 1:1000 in TPBS containing 2%
normal goat serum at 4 ◦C, overnight. After rinsing samples in 10 mM PBS for 5 min
(3 times), goat anti-human Alexa488 (Thermo Fisher Scientific) antibody diluted to 1:500
in TPBS containing 2% normal goat serum for 1 h was used to visualize the infiltrated
human immunoglobulins from the sera into spinal neurons. Before incubating the samples
with goat anti-rabbit Alexa Fluor 546 (Thermo Fisher Scientific) diluted and incubated
identically to the other secondary antibody, samples were washed in 10 mM PBS for 5 min
(3 times). Finally, stained samples were rinsed in 10 mM PBS for 5 min. Afterward, all
samples were mounted on silane-coated glass slides, covered with Fluoromount-G medium
(Sigma-Aldrich), and visualized under a confocal microscope (Eclipse C1, Nikon, Tokyo,
Japan). All digital images were uniformly processed with the two-dimensional blind
deconvolution module of the AutoQuant X program (version X2.2, Media Cybernetics,
Rockville, MD, USA); then, contrast and brightness were modified as needed to improve
image quality and reduce background noises.
4.5. Counting the Lumbar Motor Neurons on Histological Sections
After fixation, segments from the intumescence of the lumbar spinal cords were
spared for quantification of motoneuronal survival in the ventrolateral MN pools. As in
our previous experiments, the lumbar section was chosen for evaluation since hindlimb
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weakness is one of the first symptoms of MN degeneration in immune-mediated and
transgenic animal models [20,21]. Sections were placed in a 30% sucrose solution. After
cryoprotection, consecutive 10 µm thin sections were cut with a cryostat (Reichert-Jung,
Leica Biosystems, Wetzlar, Germany) and stained with cresyl violet. Estimation of the
number of MNs was performed using the optical disector method on the cresyl-violet-
stained samples. Images were recorded and examined with the Image-Pro Plus image
analysis program (version 7.0.0.591, Media Cybernetics) and a MicroPublisher 5.0 RTV
charge-coupled device camera (QImaging, Surrey, BC, Canada) attached to an Eclipse
80 i (Nikon) light microscope. The MNs were identified by their size, location in the
ventrolateral position, and their ultrastructural features. The anatomical border of the
ventrolateral pool of MNs was determined using the method described by Kong et al. [60].
The cells were counted if they met the selection criterion of the disector, which was the
presence of the nucleolus in the section in either optical plane. Counts from consecutive
sections (n = 8/animal) were pooled for animals, and the average numbers of MNs in the
lumbar segments were determined for each group.
4.6. Quantification of the Intracellular Calcium Level in the Spinal Motor Neurons
Sections were screened for the presence of the profiles of MNs in the ventral horns
of the lumbar spinal cord, and images were recorded in a JEM-1400 Flash transmission
electron microscope (JEOL, Tokyo, Japan). The relative volume of the perikarya occupied
by the EDDs representing the calcium precipitates was determined, as described previously
in the work of Meszlényi et al. [21].
4.7. Statistical Analysis
To determine the average volume occupied by EDDs within the cellular compartments
of MNs, the data derived from individual electron microscopic fields were pooled according
to animals and passive transfer groups. From each animal, 15-15 perikaryal areas were
analyzed on the TEM images of these MNs. The number of MNs on both sides of the
lumbar spinal cord was determined on cresyl-violet-stained samples (n = 8/animal), and
values were averaged per animal. Differences among multiple means of the volume
density of the EDDs were assessed by the one-way analysis of variance, followed by the
Bonferroni post hoc test. Expectation–Maximization cluster analysis was performed with
WEKA (version 3.8.3, Waikato, New Zealand) to investigate the cross-relation of the volume
density of EDDs and the loss of MNs in patients with different ALS genotypes and controls.
All statistical analyses were performed with R (version 3.6.2, R Foundation for Statistical
Computing, Vienna, Austria) with R Studio Integrated Development Environment (version
1.1.453, RStudio Inc., Boston, MA, USA) for Windows. All data are presented as mean
values ± the standard error of the means (s.e.m.).
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Abbreviations
ALS Amyotrophic lateral sclerosis
C9ORF72 Chromosome 9 open reading frame 72
CCNF G2/mitotic-specific cyclin F
EDDs Electron-dense deposits
HNRs Hexanucleotide repeat expansions
IgG Immunoglobulin G
MN Motor neuron
NEK1 Never in a mitosis A-related kinase 1
PBS Phosphate-buffered saline
SOD1 Superoxide dismutase 1
SQSTM1 Sequestosome 1
TBK1 TANK-binding kinase 1
TPBS Phosphate-buffered saline with 0.2% Triton X-100
UBQLN2 Ubiquilin 2
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